Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal β2-agonist

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 6, 2007, Pages 701-707

  Akamatsu, K ^a   Yamagata, T ^a   Takahashi, T ^b   Miura, K ^c   Maeda, S ^d   Yamagata, Y ^a   Ichikawa, T ^a   Yanagisawa, S ^a   Ueshima, K ^a   Hirano, T ^a   Nakanishi, M ^a   Matsunaga, K ^a   Minakata, Y ^a   Ichinose, M ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NTT East Tohoku Hospital   (Japan)

^c AKITA RED CROSS HOSPITAL   (Japan)

^d Jusendo General Hospital   (Japan)

Author keywords

Combination therapy; Dyspnea; Pulmonary function; Tiotropium; Transdermal 2 agonist tulobuterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; TIOTROPIUM BROMIDE; TULOBUTEROL;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPNEA; FEMALE; FLOW MEASUREMENT; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MONOTHERAPY; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; BRONCHODILATOR AGENTS; DRUG SYNERGISM; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TERBUTALINE;

EID: 34548826226     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.08.004     Document Type: Article

References (30)

1. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated, 2005.
2. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
3. van Noord J.A., de Munck D.R., Bantje T.A., Hop W.C., Akveld M.L., and Bommer A.M. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 15 (2000) 878-885
4. ZuWallack R.L., Mahler D.A., Reilly D., Church N., Emmett A., Rickard K., et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 119 (2001) 1661-1670
5. Tsukino M., Nishimura K., Ikeda A., Hajiro T., Koyama H., and Izumi T. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 53 (1998) 269-273
6. Casaburi R., Briggs Jr. D.D., Donohue J.F., Serby C.W., Menjoge S.S., and Witek Jr. T.J. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 118 (2000) 1294-1302
7. Littner M.R., Ilowite J.S., Tashkin D.P., Friedman M., Serby C.W., Menjoge S.S., et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000) 1136-1142
8. van Noord J.A., Bantje T.A., Eland M.E., Korducki L., and Cornelissen P.J. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 55 (2000) 289-294
9. Vincken W., van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
10. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26 (2005) 214-222
11. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129 (2006) 509-517
12. Uematsu T., Nakano M., Kosuge K., Kanamaru M., and Nakashima M. The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Eur J Clin Pharmacol 44 (1993) 361-364
13. Iikura Y., Uchiyama H., Akimoto K., Ebisawa M., Sakaguchi N., Tsubaki T., et al. Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. Ann Allergy Asthma Immunol 74 (1995) 147-151
14. Fukuchi Y., Nagai A., Seyama K., Nishimura M., Hirata K., Kubo K., et al. Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol. Treat Respir Med 4 (2005) 447-455
15. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
16. Mahler D.A., and Harver A. Measurement of symptoms: the benchmark of treatment. Minimizing the effects of dyspnea. J Respir Dis 8 (1987) 23-34
17. Eltayara L., Becklake M.R., Volta C.A., and Milic-Emili J. Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154 (1996) 1726-1734
18. van Noord J.A., Smeets J.J., Custers F.L., Korducki L., and Cornelissen P.J. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 639-644
19. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
20. Donohue J.F., van Noord J.A., Bateman E.D., Langley S.J., Lee A., Witek Jr. T.J., et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122 (2002) 47-55
21. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
22. Tashkin D., and Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 123 (2003) 1441-1449
23. Kume H., Kondo M., Ito Y., Suzuki R., Yamaki K., and Takagi K. Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. Clin Exp Pharmacol Physiol 29 (2002) 1076-1083
24. Horiguchi T., Kondo R., Miyazaki J., Fukumokto K., and Torigoe H. Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma. Arzneimittelforschung 54 (2004) 280-285
25. Burioka N., Miyata M., Endo M., Fukuoka Y., Suyama H., Nakazaki H., et al. Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy. Chronobiol Int 22 (2005) 383-390
26. Bestall J.C., Paul E.A., Garrod R., Garnham R., Jones P.W., and Wedzicha J.A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54 (1999) 581-586
27. Mahler D.A., Weinberg D.H., Wells C.K., and Feinstein A.R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984) 751-758
28. Jones P.W., Quirk F.H., Baveystock C.M., and Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145 (1992) 1321-1327
29. Barnes P.J. Tiotropium bromide. Expert Opin Invest Drugs 10 (2001) 733-740
30. Hvizdos K.M., and Goa K.L. Tiotropium bromide. Drugs 62 (2002) 1195-1203